Will Bupa Arabia or Tawuniya cover this?

Each plan handles named-patient oncology imports case-by-case. Some plans cover BRCA-targeted prostate cancer therapies on the formulary at meaningful levels; many require pre-authorization with the molecular pathology report and the clinical justification letter. Cash-pay is the default posture, with reimbursement pursued after delivery.

Do I need BRCA testing before initiation?

Yes. The FDA label requires BRCA mutation confirmation before the first dose, through an FDA-approved companion diagnostic such as FoundationOne CDx. If your testing was done at a Saudi or international laboratory, the molecular pathology report needs to be reviewed for compatibility with the labeled requirement before the PIP file is opened.

What is the MDS and AML warning?

Myelodysplastic syndrome and acute myeloid leukemia have been reported with niraparib and other PARP inhibitors, including fatal cases, and this risk is described in the FDA label as a warning. Long-term hematologic surveillance is part of the standard monitoring plan. The treating oncologist owns this monitoring.

Why Akeega versus separate niraparib and abiraterone?

A single fixed-dose tablet simplifies administration and adherence relative to two separately prescribed and separately sourced medicines. The MAGNITUDE evidence base is specifically for the combination. The treating oncologist makes the selection between the fixed-dose combination, the olaparib-plus-abiraterone combination, the talazoparib-plus-enzalutamide combination, and other regimens.

Can I take Akeega with food?

No. Per the FDA label, Akeega is taken on an empty stomach. No food should be consumed for at least one hour before or two hours after each dose. Abiraterone exposure increases significantly with food and that exposure increase is associated with toxicity. This is a patient-administration discipline, not a clinical-decision question.

Indicative drug-only band: USD 11,500 to 13,000 per month. Delivered quote within 24h.Get my quote

Akeega access in Saudi Arabia

How Saudi patients with BRCA-mutated metastatic prostate cancer reach Akeega (niraparib plus abiraterone acetate) through the SFDA Personal Importation Program.

Quick orientation

Akeega is the first fixed-dose combination oral tablet of niraparib (a PARP inhibitor) and abiraterone acetate (a CYP17 androgen-biosynthesis blocker), approved by the U.S. FDA on August 11, 2023 for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) and expanded in December 2025 to BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). Both indications require BRCA mutation confirmation through an FDA-approved companion diagnostic such as FoundationOne CDx. In Saudi Arabia, Akeega has no SFDA marketing authorization. Patients in the Kingdom who have completed BRCA testing and have a treating oncologist at KFSH&RC, KAMC, MNGHA, HMG, or Saudi German reach Akeega through the SFDA Personal Importation Program (PIP). Reserve Meds is the U.S.-side coordinator. The treating oncologist owns the BRCA confirmation, the prescription, and the monitoring plan.

How Akeega reaches patients in Saudi Arabia

Akeega (niraparib plus abiraterone acetate fixed-dose dual-action tablet, FDA-approved August 2023 for BRCA-mutated metastatic castration-resistant prostate cancer) is not currently visible on the SFDA registered-drug list at sfda.gov.sa/en/drugs-list as of 2026-05-31. Saudi residents access Akeega through Personal Importation of Medicines (the SFDA Clearance Permit for Personal Use) administered under SFDA Document Drug-6567E, published at sfda.gov.sa Drug-6567E PDF, with the Arabic-equivalent at Drug-6567EE. A parallel hospital-led Special Access Programme exists for institutional importation (KFSHRC, KFMC, KAMC). The application is submitted via the SFDA electronic services portal. The Akeega-specific clinical justification must document confirmed BRCA1 or BRCA2 mutation status (germline or somatic) per the FDA label, the mCRPC line of therapy, prior androgen-receptor-pathway-inhibitor exposure where applicable, and the prescribing oncologist's licensure with the Saudi Commission for Health Specialties. The supporting medical report must be approved by the treatment institution and dated within 6 months of submission (SFDA Drug-6567E hard requirement). Quantity matches a 3-month supply per permit. SFDA electronic services target same-day to several-working-day turnaround when documentation is complete.

Where Akeega is dispensed in Saudi Arabia

Akeega is an oral adult-oncology agent administered outpatient with monthly haematology, liver function, blood pressure, and PSA surveillance. Saudi tertiary oncology nodes equipped for this profile include King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh, Jeddah, and Madinah, with the Cancer Centre of Excellence and the Department of Medical Oncology and Genitourinary Oncology service, at kfshrc.edu.sa; King Fahad Medical City (KFMC) Comprehensive Cancer Center in Riyadh at kfmc.med.sa, the MOH reference centre for oncology; King Abdulaziz Medical City (KAMC) Princess Noorah Oncology Center under the Ministry of National Guard Health Affairs in Riyadh and Jeddah; Prince Sultan Military Medical City Department of Oncology in Riyadh; King Fahad Specialist Hospital Dammam Department of Oncology in the Eastern Province; and King Abdulaziz University Hospital Department of Oncology in Jeddah. KFSHRC is the most-frequent dispensing node for cross-border specialty oncology imports and treats approximately one-quarter of Saudi cancer cases annually; the institution publishes departmental chairs and holds the institutional importation licence under the SFDA Special Access Programme. BRCA testing capacity is available at KFSHRC, KFMC, and KAMC through institutional clinical genetics services.

What Akeega costs in Saudi Arabia

The US reference WAC for Akeega is in the range of USD 16,000 to USD 18,000 per 30-day supply at the labelled dose per Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual WAC runs USD 200,000 to USD 220,000. No public SAR benchmark for Akeega is observed on the SFDA drugs list or via the National Unified Procurement Company (NUPCO) at nupco.com as of 2026-05-31; the drug is not currently SFDA-registered. Do not estimate. Price snapshot: 2026-05-31. The Saudi Riyal is pegged to the US Dollar at approximately 3.75 SAR per USD; the peg removes FX volatility from the price calculation. Cost layers: ambient-temperature international logistics into Saudi Arabia (low to mid four-figure USD; Akeega is a stable oral tablet), SFDA personal-import clearance fees (nominal), the dispensing hospital's oncology consultation and surveillance fees, and the Reserve Meds concierge fee itemised separately. For Saudi nationals treated at KFSHRC, KFMC, or KAMC under MOH funding, the drug-product cost is typically borne by the institutional channel where the Special Access Programme has been invoked; out-of-pocket exposure is materially lower than for non-citizens.

Funding and access barriers for Akeega in Saudi Arabia

Saudi citizens receive public health services without direct charge at MOH facilities and at specialty referral centres (KFSHRC, KFMC, KAMC); specialty oncology and rare-disease care is delivered under MOH funding through NUPCO procurement, generally without OOP cost to the patient. The Council of Health Insurance (CHI) at chi.gov.sa regulates the mandatory cooperative health insurance scheme covering private-sector employees and dependents (predominantly residents and expatriates); CHI publishes the Essential Benefits Package which is the floor for drug coverage. Major Saudi cooperative health insurers (Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative Insurance, Al Rajhi Takaful, Walaa Cooperative Insurance, SAICO) extend coverage with higher-tier policies; named-patient unregistered-drug imports require prior authorisation and are coverage-tier dependent. For Saudi citizens, the Akeega case typically routes through KFSHRC or KFMC under the institutional Special Access Programme with MOH/NUPCO funding (subject to clinical committee approval based on confirmed BRCA mutation status and prior-therapy documentation). For expatriate patients on cooperative insurance, the funding path depends on the policy tier; out-of-pocket exposure is most material for plan exclusions, sub-limits on specialty oncology drugs, and named-patient imports not pre-authorised. King Salman Humanitarian Aid and Relief Centre (KSrelief) funds case-by-case treatment for non-citizens under specified humanitarian programmes.

Recent regulatory and access news for Akeega

EMA (CHMP) issued a positive opinion for Akeega in 2024; the European Public Assessment Report is at ema.europa.eu/medicines/Akeega. The FDA has retained the BRCA-mutated mCRPC label since the August 2023 approval; no major label expansion has been announced through May 2026 per the FDA approval page at accessdata.fda.gov/scripts/cder/daf. The SFDA News feed at sfda.gov.sa/en/news does not show an Akeega-specific bulletin over the last 12 months as of 2026-05-31. The SFDA Drug-6567E personal-import guideline remains the operative reference for the patient-led pathway; the SFDA continues to issue periodic clarifications.

Where Reserve Meds fits in Akeega cases

Reserve Meds is the U.S.-side concierge coordinator. For an Akeega case in Saudi Arabia, Reserve Meds confirms eligibility and case fit including BRCA documentation review within 24 to 48 hours, sends the documentation kit to your treating oncologist, coordinates U.S. specialty pharmacy sourcing through Janssen's authorized limited-distribution channel (Onco360 is the principal partner), manages ambient-temperature international logistics with heat-excursion logging, and assigns a single named Concierge Patient Coordinator who stays with the patient and family across monthly reorders. Reserve Meds does not file the PIP application, does not prescribe, does not interpret BRCA results, and does not advise on the choice between PARP combinations. The clinical authority remains with the SCFHS-licensed oncologist. The regulatory authority remains with SFDA. The dispensing remains with the licensed Saudi hospital pharmacy.

Next step

If you have BRCA-mutated metastatic prostate cancer and the treating oncologist has discussed Akeega, the intake is the entry point. Reserve Meds responds within 24 to 48 hours with a documentation kit for your oncologist and an indicative cost range. The firm quote follows after BRCA documentation review and prescriber confirmation of the dose plan.

Start your case Or message us on WhatsApp

Reserved for you.